Buy & Sell Royal Bank of Canada (RY) – Royal Bank of Canada Price Today
Aura AI Summary
Key Stats
- $253.98BMarket Cap
- FinancialsSector
- -9.09%3M Drawdown
- -Enterprise Value
- 2.63%Dividend Yield
- 5% Buy | 95% SellTrading Activity
- 44 daysTypical Hold Time
Royal Bank of Canada (RY) is currently valued at a market capitalization of $253.98B. Over the past 52 weeks, Royal Bank of Canada has traded between a low of $121.8 and a high of $182.28, highlighting its annual price range. Over the past three months, Royal Bank of Canada has recorded a drawdown of -9.09%, reflecting recent price volatility. Royal Bank of Canada offers a dividend yield of 2.63%, with the most recent dividend of $1.64 paid on 23 Apr 26. On average, investors hold Royal Bank of Canada for approximately 44 days, indicating typical investor behavior on the platform.
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Most Recent News
AI in life sciences market set to grow at 20% CAGR, reaching $11.5B by 2034 driven by drug discovery and data analytics.
The global AI in life sciences market is projected to expand at a compound annual growth rate (CAGR) of about 20% from 2026 to 2034, reaching an estimated value of $11.5 billion. This growth is fueled by increasing demand for faster drug discovery, p...
Global colorectal cancer diagnostics and therapeutics market to grow at ~9% CAGR, reaching $73B by 2034
The global colorectal cancer diagnostics and therapeutics market is projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching an estimated value of $73 billion by 2034. This growth is driven by rising c...
New data shows Wegovy pill leads to significant long-term weight loss and improved physical function.
Novo Nordisk presented new phase 3 trial data showing that adults taking the Wegovy pill (oral semaglutide 25 mg) achieved meaningful weight loss, with early responders losing up to 21.6% body weight by week 64. Even those not classified as early res...